We still maintain partnering with "FastForward", I believe, one vital funding source among other "private investors" and fund-raising efforts with DioGenix...

Quote:

---

Collaborative Fund Progress


Fast Forward has formed a 5-year $19 million strategic alliance with EMD Serono/Merck KGaA to speed drug development through the MS pipeline through mutually agreed upon seed-to-early-stage projects. In the first year of the collaboration, 4 drug development programs in the area of neural repair and protection were selected for funding. Under the terms of the collaboration, EMD Serono/Merck KGaA will have the option to in-license these programs at their completion. A list of the projects is below.

---

http://www.nationalmssociety.org/Research/Res...Funded-(1)

Quote:

---

Provides funding opportunities of up to $500,000 annually (direct and indirect costs) to commercial entities for the development of MS treatments. Funding availability is world-wide, and follows an annual RFP cycle.

---

Quote:

---

This funding will allow DioGenix to determine if the same approach will work in blood samples.

---

http://www.clpmag.com/2012/11/diogenix-fast-f...x-for-ms2/

“We are pleased to partner with DioGenix in the advancement of this innovative technology for MS,” said Timothy Coetzee, Ph.D., Chief Research Officer of the National MS Society. “Fast Forward’s partnership with DioGenix reflects our commitment to develop new tools and technologies to assist physicians in making earlier and more confident diagnostic and treatment decisions for patients coping with neurological diseases, in particular with MS. We believe that these types of innovative programs are critical to improving the quality of life for people living with these diseases.”


http://diogenix.com/about/partners/